Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast CancerEva Thomas, Miguel Martín, Valentina Guarneri et al.|Journal of Clinical Oncology|2007Cited by 290
Clinical and immune responses to neoadjuvant fulvestrant with or without enzalutamide in ER+/Her2− breast cancerAnthony Elias, Jennifer K. Richer, Alyse Staley et al.|npj Breast Cancer|2024Cited by 9
Abstract CT144: Randomized phase II trial of preoperative fulvestrant with or without enzalutamide for ER+/Her2- breast cancerAnthony Elias, Jennifer K. Richer, Alyse Staley et al.|Cancer Research|2023Cited by 0
Abstract PS18-07: Differential odds of response in ILC versus IDC correlate with changes in the TIME in a phase II trial of pre-operative fulvestrant with or without enzalutamideJennifer K. Richer, Dexiang Gao, Anthony Elias et al.|Clinical Cancer Research|2025Cited by 0
Abstract P2-04-27: Development & Validation of RSC4All: an Artificial Intelligence-driven Machine Learning Nomogram Enhanced with Synthetic Data to Predict RSClin® Results & Guide Adjuvant Treatment of Node-negative HR-positive/HER2-negative Early Breast CancerFlavia Jacobs, Alberto Zambelli, Saverio D’Amico et al.|Clinical Cancer Research|2025Cited by 0